Sareen et al. (2022) conducted a meta-analysis on the predictive performance of biomarkers and found that five studies involving 541 GBM patients with IDH1 mutation showed a significant improvement in OS for patients with IDH1 mutation. Chai et al. (2021) performed a Kaplan-Meier survival analysis on 50 patients treated with TMZ, and the results revealed that patients with a methylation level of ≥30% had the longest progression-free survival (PFS) and OS. Here, IDH1 is linked to glioblastoma.